Philip Morris Products S.A.

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Philip Morris Products S.A. sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 1 currently recruiting 9 completed top decile by trial count

Philip Morris Products S.A.: 11 sponsored US clinical trials, 1 recruiting.

Philip Morris Products S.A. sponsors 11 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 9 completed. The most-studied condition in this pipeline is Smoking, with 2 trials.

Top-decile sponsor footprint

Philip Morris Products S.A. ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 65/100

9 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

11 total, page 1 of 1

RECRUITING NA

Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS

NCT07108166
TERMINATED NA

Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

NCT05569005
COMPLETED NA

Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes

NCT05383508
COMPLETED NA

Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of P4M3 Variants

NCT03379740
COMPLETED NA

Prefatory Study to Explore Changes in Nasal Mucociliary Clearance and to Standardize Nasal Scraping Procedure

NCT03086707
COMPLETED NA

User Acceptability of a Nicotine Lactate Delivery System (P3L)

NCT02643693
COMPLETED NA

A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2

NCT02649556
COMPLETED

A Smoking Cessation Study to Understand the Biological and Functional Changes After One Year of Smoking Cessation

NCT02432729
COMPLETED NA

Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks

NCT02396381
COMPLETED NA

Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting

NCT01989156
COMPLETED NA

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)

NCT01967719

Therapeutic Areas

Smoking 2
Nicotine 1
Nicotine Vaping 1
Vaping 1
Tobacco Use 1
COPD 1

What is open in the Philip Morris Products S.A. pipeline

1 recruiting of 11 indexed (9% open); 9 completed (82%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Smoking (2 trials), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Philip Morris Products S.A.: open-pipeline peers nationwide

Peers matched on 11 registered trials and 9% open enrollment, not the therapeutic-area sidebar.

Philip Morris Products S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 020406080 0%2%4%6%8%10% Total trials Recruiting share Philip Morris Products S.A.Aderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeAlkermesDBV TechnologiesFlorida Gulf Coast UniversityGenfit
Philip Morris Products S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Philip Morris Products S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 9% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Philip Morris Products S.A. page

11 registered trials is a research-attention snapshot, not an endorsement of Philip Morris Products S.A. or any single study.

  • 1 of Philip Morris Products S.A.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Smoking is the condition Philip Morris Products S.A. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Smoking trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Philip Morris Products S.A. pipeline card: 11 registered trials from official public datasets.Report a data error.